Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Probiotics in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the NICU~* Written parental consent~* Birth weight \< 2000 grams~* Hemodynamically stable~* \< 48 hours of age~Exclusion Criteria:~* Evidence or suspicion of congenital intestinal obstruction or perforation~* Prenatal or postnatal diagnosis of gastroschisis, large omphalocele, or congenital diaphragmatic hernia~* Major congenital heart defects~* Anticipated transfer to a NICU not involved in the study

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 48 Hours
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): 5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital. Patients fed through NG tube will be administered 5 drops of placebo through the NG tube followed by a 0.5 cc of a normal saline flush. Patients taking PO feeds will be administered 5 drops of placebo in posterior oropharynx after secretions have been suctioned.
- 2 (Type: EXPERIMENTAL): 5 drops of Lactobacillus reuteri DSM 17938 from an oil based suspension will be administered once a day until death or discharge home. Patients with NG feeds will be administered the probiotic in the amount of 5 drops through the NG tube followed by 0.5 cc of a normal saline flush. Patients with PO feeds will be administered 5 drops of the probiotics in the posterior oropharynx after secretions have been suctioned. If feeds are temporarily suspended because of feeding intolerance or NEC, the probiotic may be re-started once feeds are re-started.

Based on this trial design, predict the completion outcome and termination type (if applicable).